Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Chelsea’s Northera Clears FDA But With A Confirmatory Trial Requirement

19 Feb 2014

• By Cathy Dombrowski

Related Content

Not The Next <em>Avastin</em>? Plan For New <em>ProAmatine</em> Studies Would Negate Shire’s Withdrawal Hearing Request

19 Dec 2011

<em>Northera</em> Ongoing Trial May Satisfy FDA Request For More Efficacy Data, Chelsea Says

29 Mar 2012

Durability Questions Mean<em> Northera</em> Should Be Limited To Short-Term Use, Panel Says

20 Jan 2014

Related Companies

Chelsea Therapeutics International, Ltd.

Takeda Pharmaceutical Co. Ltd.

Sumitomo Pharma Co., Ltd.

Additional Topics

United States Regulation Approvals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.